Is AstraZeneca plc set to lose out to Hikma Pharmaceuticals plc and BTG plc?

Should you sell AstraZeneca plc (LON: AZN) and pile into Hikma Pharmaceuticals plc (LON: HIK) and BTG plc (LON: BTG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the last three months, shares in AstraZeneca (LSE: AZN) have performed relatively poorly. They’re down by almost 8% and with sector peers such as Hikma (LSE: HIK) and BTG (LSE: BTG) rising by 5% and 2%, respectively, during the same time period, many investors may be wondering whether it’s time to sell AstraZeneca and pile into two of its pharmaceutical rivals.

On the one hand, selling AstraZeneca could be viewed as a sound move. That’s because the company is forecast to report a further fall in its earnings in both the current year and next year as a loss of patents on key, blockbuster drugs continues to hurt its top-line performance. During this period, it would be rather unsurprising for AstraZeneca’s share price to come under further pressure as investors begin to price-in yet more pain on the earnings front.

However, beyond the next two years AstraZeneca has huge appeal. That’s because it has invested heavily in its drug pipeline through major acquisitions. They’ve strengthened its growth potential and while it looks as though it will take more than a couple of years for the company to deliver positive earnings growth, it appears to be on the path to doing so. And with AstraZeneca’s balance sheet and cash flow being very strong, it has the financial firepower to make many more sizeable acquisitions to further bolster its long-term profit outlook.

What’s the alternative?

Clearly, the likes of Hikma and BTG have significant appeal for long-term investors. In the case of the former, it’s forecast to endure a tough 2016 as a result of an expected fall in earnings of 12%. However, looking ahead to next year, Hikma is due to reverse this with growth of 36%. This has the potential to significantly improve investor sentiment in the company. And with its shares trading on a price-to-earnings-growth (PEG) ratio of just 0.5, there seems to be considerable scope for an upward rerating due in part to Hikma having such a wide margin of safety.

Similarly, BTG is set to increase its earnings over the next two years with growth of 17% in the current year and 25% next year being pencilled-in by the market. This is an exceptionally strong rate of growth and has the potential to positively catalyse investor sentiment in BTG. As with Hikma, BTG trades on a relatively low PEG ratio, which affords it a wide margin of safety. Therefore, there’s upside potential from BTG’s PEG of 0.9, while the risk of a major fall in its share price is somewhat limited by having such an appealing valuation.

So, while BTG and Hikma offer better growth potential in the short run and have outperformed AstraZeneca in the last three months, AstraZeneca has a very bright long-term future. Furthermore, it has a size and scale advantage over its peers, with it arguably having more diversity and financial firepower through which to improve its pipeline. As such, AstraZeneca still seems to be the best buy of the three, although Hikma and BTG offer excellent risk/reward ratios.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca, BTG, and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »